Armin H. Reitmair, Ph.D., MBA

** ****** *****, ******, **, U.S.A.

T: +1-949-***-****; F: +1-253-***-****; ac26so@r.postjobfree.com

SUMMARY

Eighteen years industry experience in Pharma, Diagnostics, and Nanobiotech: executive leadership, $3.5M fund raising, finance & accounting, negotiations, product development, drug discovery (Oncology and Ophthalmology) and research

High-energy strategic thinker with proven ability to succeed in pressured environments; dynamic problem solver with

creative mindset as well as exceptional analytical and interpersonal skills who can communicate across boundaries

Established multiple industry/university collaborations; presented at conferences, trade shows, and summits

Ideally suited to management roles requiring balanced strengths in technical and global corporate leadership skills

Fluent in English, German, French, Spanish, intermediate proficiency in Italian; dual citizenship (Germany, U.S.)

Nineteen publications in international peer-reviewed scientific journals

One issued U.S. patent, two pending, two provisionals

EXPERIENCE

NESHER TECHNOLOGIES, INC. Los Angeles, CA

Chief Executive Officer/Director of Business Development 2013 -

Developed business plan including fund-raising strategy and secured $3.5M in federal grant (part-time since 2005)

funding for privately held nanobiotech/medical device start-up company (www.neshertech.com)

Led team of 9 employees and 10+ consultants; determined strategic direction and managed corporate activities

PI (Principal Investigator) and Co-PI on 13 NIH (National Institutes of Health) small business grants for research

in context with commercialization of proprietary cutting-edge technology for multiplex single molecule detection

Negotiated exclusive license for UCLA-held patent at highly favorable terms, identified various market opportunities within $60B In Vitro Diagnostics (IVD) and $2B Academic Research markets, and achieved the company's first sale

ALLERGAN, INC. Irvine, CA

Principal Scientist 2008 - 2013

Cross-functional team management within Drug Discovery, Drug Development, and Intellectual Property departments

Selected drug candidates for preclinical development within fast-growing $20B Ophthalmic Drugs market

Senior Scientist 2003 - 2007

Established innovative automated screening system for high-throughput drug discovery, triplicating lead identification and significantly reducing screening costs (recognized with "Award for Excellence")

Proposed, planned, and executed Mechanism-of-Action studies of drug candidates for preclinical development

to assist IND (Investigational New Drug) filings with the FDA (Food and Drug Administration)

Scientist 1999 - 2003

Key member of the Cancer Research Working Group within the Dept. of Biological Sciences

Assessed new proprietary compounds as effective anti-cancer drugs resulting in identification of pharmaceutical

lead compounds through cell-based assays and animal studies, addressing $110B Cancer Drug market

INSTITUTE OF GENETICS AND MOLECULAR AND CELLULAR BIOLOGY Strasbourg, France

Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC); Université Louis Pasteur 1996 - 1999

Postdoctoral Fellow

Analyzed the Mechanism-of-Action on the genetic level of retinoic acid treatment of leukemia patients which led to development of TRAIL-receptor agonists (TRAs) as novel anti-cancer drugs

Research in the Nuclear Receptor Group (Profs. Chambon and Gronemeyer), funded by awards from the prestigious international "Human Frontiers Science Program (HFSP)" and the French "Foundation for Medical Research (FRM)"

EDUCATION

UCLA ANDERSON SCHOOL OF MANAGEMENT - UNIVERSITY OF CALIFORNIA LOS ANGELES

MBA (General Management and Entrepreneurship) GPA: 3.72 June 2004

Created business plan for proposed biotech/medical device company

Knapp Venture Capital Competition semifinalist

UNIVERSITY OF ERLANGEN-NUREMBERG (Germany)/UNIVERSITY OF TORONTO (Canada)

Ph.D. (Molecular Biology and Genetics) Summa cum laude July 1996

Created a novel genetically engineered cancer mouse model resembling a human hereditary cancer syndrome, which received widespread international attention as well as patent protection for drug development and carcinogen testing

Research in Prof. T. Mak's renowned lab at the Ontario Cancer Institute/Amgen Research Institute/Princess

Margaret Hospital in Toronto, funded by a 3-year fellowship of the "German Academic Exchange Service (DAAD)"

ADDENDUM

Expertise and Technical Skills:

Corporate leadership and business administration; cross-functional team management; business plan development; fundraising; all aspects of grantsmanship; finance & accounting; negotiations; product development; drug discovery (Oncology & Ophthalmology), research on molecular changes in cancer; biology of retinoids, prostaglandins & sphingolipids (ligands for nuclear receptors and G-protein coupled receptors (GPCRs)); HTS (high throughput screen)-based lead identification; single molecule detection (SMD) based on Alternating Laser EXcitation (ALEX) fluorescence spectroscopy; knock-out mice models; antibody development; characterization of apoptosis; cDNA library generation/screening; DNA microarrays; Differential Display (DD); RNase protection assays (RPA); FACS analysis; Luminex®-assays; ELISA; PKC-, NF B-, cAMP-, MTT-, BrdU-assays; clonogenic assays; all standard molecular biology techniques (DNA-cloning, Southern/Northern/Western blot, sequencing, PCR, real-time RT-PCR, cell culture, transient and stable transfections, etc.); Bioinformatics (DNA sequence assembly, promoter analysis, restriction enzyme maps, primer optimization (Oligo v.7), GCG, BLAST, VIBE, ActivityBase, SARview, Sequencer, GenSpring)

U.S. Federal Grant Awards (Total of $3,524,266; Success rate of 38% vs. average of 15-20%):

2015-2016 1R43AR068888-01 (Principal Investigators: Reitmair A, Kim T) $150,000

NIH (National Institutes of Health)/NIAMS (Nat’l Inst. of Arthritis and Muscosceletal and

Skin Diseases)

microRNA- and Autoantibody-based Multiplex Assay for Systemic Lupus Erythematosus

2015-2016 1R43DK107169-01 (Principal Investigators: Kim T, Reitmair A) $150,000

NIH/NIDDK (Nat’l Inst. of Diabetes and Digestive and Kidney Diseases)

Autoantibody- and microRNA-based Next-Gen Multiplex Test for Type 1 Diabetes

2013-2015 1R43AG044951-01 (Principal Investigators: Kim T, Reitmair A) $462,692

NIH/NIA (Nat’l Inst. on Aging)

Multiplexed Protein & miRNA Biomarker-based Next-gen Test for Alzheimer’s Disease

2013-2014 1R43AR064649-01 (Principal Investigators: Kim T, Reitmair A) $150,000

NIH/NIAMS

Multiplex ALEX-based Test for Protease Activity Profiling in Arthritic Joints

2012-2014 1R43CA167896-01 (Principal Investigators: Kim T, Reitmair A) $321,100

NIH/NCI (National Cancer Institute)

ALEX for fast ultrasensitive multiplexed detection & quantification of microRNAs

2012-2013 1R43AI094980-01A1 (Principal Investigators: Kim T, Reitmair A) $119,532

NIH/NIAID (Nat’l Inst. of Allergy and Infectious Diseases)

Fast accurate ultrasensitive in vitro assay to determine BoNT potency & stability

2009-2012 1R43AI078635-01A1 (Principal Investigators: Kim T, Reitmair A) $598,110

NIH/NIAID

Rapid, Highly Multiplexed and Sensitive Blood Test for Drug-resistant Bacteria

2009-2012 1R43GM085962-01A1/-01A1S1 (Principal Investigators: Kim T, Reitmair A) $520,120

NIH/NIGMS (National Institute of General Medical Sciences)

Compact ALEX-based Reader for Highly Multiplexed Single Biomolecule Detection

2009-2011 1R43RR026190-01 (Principal Investigators: Kim T, Reitmair A) $190,404

NIH/NCRR (National Center for Research Resources)

Real-time Single-Molecule Analysis for Transient Molecular Complex Characterization

2008-2009 1U54AI065359 subaward No. 2006-1756-2 (Principal Investigator: Reitmair A) $150,000

NIH/PSWRCE (Pacific Southwest Regional Center of Excellence)

Multiplexed Fast Ultrasensitive and Cost-effective Serum Test for Botulinum Toxins

2007-2009 1R41NS060231-01 (Principal Investigator: Reitmair A) $415,209

NIH/NINDS (Nat’l Inst. of Neurological Disorders and Stroke)

Highly Multiplexed Sensitive Specific & Automated Test for Neurogenetic Disorders

2006-2008 1U54AI065359 subaward No. 2006-1756 (Principal Investigator: Reitmair A) $197,099

NIH/PSWRCE

Ultrasensitive/specific Rapid Low-cost Mix-and-read Serum Test for Botulinum Toxins

2006-2008 1R41CA121853-01 (Principal Investigator: Reitmair A) $100,000

NIH/NCI

Multiplexed Ultrasensitive Mix-and-Read Tumor Marker Quantification Assays

Other Awards and Fellowships:

2008 Research and Drug Discovery award from Allergan, Inc. (USA): "Award for Excellence"

1997-1999 Two-year fellowship from the "Human Frontiers Science Program - HFSP"

(highly selective international fellowship, funded by Japan, USA, Canada, and

various EU countries; supports top 10-15% of qualified applicants)

1993-1996 Three-year fellowship from the "German Academic Exchange Service"

("Deutscher Akademischer Austauschdienst – DAAD"; national granting agency;

supports top 15-20% of qualified applicants)

1999 Research award of the "Foundation for Medical Research"

("Fondation pour la Recherche Médicale – FRM"; France)

1989 Outstanding student award of the "Oskar Karl Forster-Foundation"

("Oskar Karl Forster-Stiftung"; Germany)

Languages:

German: mother tongue

1999 French: "Diplôme Approfondi de Langue Française - DALF"

1998 "Diplôme d'Etudes en Langue Française - DELF" (1er/2e degré)

(national diplomas by the French Ministry of National Education)

1992 English: "Test of English as a Foreign Language - TOEFL"

(worldwide English proficiency test; Princton, NJ, USA)

1991 "Certificate of Proficiency in English" (University of Cambridge/UK)

1989 Spanish: "Allgemeines Fremdsprachenzertifikat für die Sprache Spanisch"

(Spanish language certificate of the University of Erlangen-Nuremberg)

Italian: intermediate proficiency

Patents:

Reitmair A, Kim T, Partono S: "Methods and Compositions for Multiplexed and Ultrasensitive MicroRNA Detection"; Patent Application No. PCT/US2012/062202; Oct 26, 2012 (Publication Number: WO/2013/063454; Publication Date: May 2, 2013; International Class: C12Q 1/68); Assignee: Nesher Technologies, Inc.

Reitmair A, Kim T: "Fluorescence Barcoding for Molecule Detection"; U.S. Provisional Patent Application No. 61/576,897; Dec 16, 2011; Assignee: Nesher Technologies, Inc.

Reitmair A, Kim T: "Detection of Low Abundance Proteins"; U.S. Provisional Patent Application No. 61/576,889; Dec 16, 2011; Assignee: Nesher Technologies, Inc.

Reitmair A, Sachs G, Im W-B: "Screening Method for EP2/EP4 Modulators"; U.S. Patent Application No. 13/158,167; Jun 20, 2011; Assignee: Allergan, Inc.

Mak TW and Reitmair A: "MSH2 Disrupted Mice Develop Lymphomas"; U.S. Patent No. 5,907,079; May 25, 1999; Assignee: Amgen, Inc.

Scientific Publications:

Kim T, Reitmair A (2013) Non-coding RNAs: Functional aspects and diagnostic utility in oncology. International Journal of Molecular Sciences 14(3): 4934-68

Yim SW, Kim T, Laurence TA, Partono S, Kim D, Kim Y, Weiss S, Reitmair A (2012) Four-color alternating laser excitation single-molecule fluorescence spectroscopy for next-generation biodetection assays. Clinical Chemistry 58(4):707-16

Reitmair A, Sachs G, Im WB, Wheeler LA (2011) C6orf176: a novel possible regulator of cAMP-mediated gene expression. Physiological Genomics 44:152-61

Reitmair A, Lambrecht NW, Yakubov I, Nieves A, Old D, Donde Y, Dinh D, Burk R, Sachs G, Im WB, Wheeler LA (2010) Prostaglandin E2 receptor subtype EP2- and EP4-regulated gene expression profiling in human ciliary smooth muscle cells. Physiological Genomics 42: 348–360

Reitmair A, Shurland D-L, Tsang K-Y, Chandraratna RA, Brown G (2005) Retinoid-related molecule AGN193198 potently induces G(2)M arrest and apoptosis in bladder cancer cells. International Journal of Cancer 115(6): 917-923

Keedwell RG, Zhao Y, Hammond LA, Wen K, Qin S, Atangan LI, Shurland D-L, Wallace DMA, Bird R, Reitmair A, Chandraratna RAS, Brown G (2004) An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium. British Journal of Cancer 91: 580-588

Keedwell RG, Zhao Y, Hammond LA, Qin S, Tsang KY, Reitmair A, Molina Y, Okawa Y, Atangan LI, Shurland DL, Wen K, Wallace DM, Bird R, Chandraratna RA, Brown G (2004) A retinoid-related molecule that does not bind to classical retinoid receptors potently induces apoptosis in human prostate cancer cells through rapid caspase activation. Cancer Research 64(9): 3302-3312

Altucci L, Rossin A., Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H (2001) Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nature Medicine 7(6): 680-686

Jenab-Wolcott J, Rodriguez-Correa D, Reitmair AH, Mak T, Rosenberg N (2000) The absence of Msh2 alters Abelson virus pre-B-cell transformation by influencing p53 mutation. Molecular and Cellular Biology 20(22): 8373-8381

Lowsky R, Magliocco A, Ichinohasama R, Reitmair A, Scott S, Henry M, Kadin ME, DeCoteau JF (2000) MSH2-deficient murine lymphomas harbor insertion/deletion mutations in the transforming growth factor beta receptor type 2 gene and display low not high frequency microsatellite instability. Blood 95(5): 1767-1772

Andrew SE, McKinnon M, Cheng BS, Francis A, Penney J, Reitmair AH, Mak TW, Jirik FR (1998) Tissues of Msh2 deficient mice demonstrate hypermutability on exposure to a DNA methylating agent. Proceedings of the National Academy of Sciences (USA) 95(3): 1126-1130

Cranston A, Bocker T, Reitmair A, Pallazzo J, Wilson T, Mak TW, Fishel R (1997) Female embryonic lethality in mice nullizygous for both Msh2 and p53. Nature Genetics 17(1): 114-118

Andrew SE, Reitmair AH, Fox J, Hsiao L, Francis A, McKinnon M, Mak TW, Jirik FR (1997) Base transitions dominate the mutational spectrum of a transgenic reporter gene in Msh2 deficient mice. Oncogene 15(2): 123-129

Reitmair AH, Risley R, Bristow RG, Wilson T, Ganesh A, Jang A, Peacock J, Benchimol S, Hill RP, Mak TW, Fishel R, Meuth M (1997) Mutator phenotype in Msh2 deficient murine embryonic fibroblasts. Cancer Research 57(17): 3765-3771

Lowsky R, Decoteau JF, Reitmair AH, Ichinohasama R, Dong WF, Xu Y, Mak TW, Kadin ME, Minden MD (1997) Defects of the mismatch repair gene MSH2 are implicated in the development of murine and human lymphoblastic lymphomas and are associated with the aberrant expression of Rhombotin-2 (Lmo-2) and Tal-1 (SCL). Blood 89(7): 2276-2282

Reitmair AH (1997) Targeted gene inactivation via homologous recombination: Generation and early characterization of a mouse strain deficient for the tumour suppressor gene Msh2. - Gezielte Geninaktivierung mittels homologer Rekombination: Herstellung und frühe Charakterisierung eines für das Tumorsupressorgen Msh2 defizienten Mausstammes. Edition Wissenschaft, Reihe Biologie 87, Tectum Verlag Marburg (ISBN 3-89608-987-0) (doctoral thesis)

Hakem R, de la Pompa J, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, Firpo E, Hui CC, Roberts J, Rossant J, Mak TW (1996) The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85(7): 1009-1023

Reitmair AH, Redston M, Cai JC, Chuang T, Bjerknes M, Cheng H, Hay K, Gallinger S, Bapat B, Mak TW (1996) Spontaneous intestinal carcinomas and skin neoplasms in Msh2 deficient mice. Cancer Research 56(16): 3842-3849

Reitmair AH, Cai JC, Bjerknes M, Redston M, Cheng H, Pind MTL, Hay K, Mitri A, Bapat BV, Mak TW, Gallinger S (1996) MSH2 deficiency contributes to accelerated APC mediated intestinal tumorigenesis. Cancer Research 56(13): 2922-2926

Reitmair AH, Schmits R, Ewel A, Bapat B, Redston M, Mitri A, Waterhouse P, Mittrücker H-W, Wakeham A, Liu B, Thomason A, Griesser H, Gallinger S, Ballhausen WG, Fishel R, Mak TW (1995) Msh2 deficient mice are viable and susceptible to lymphoid tumours. Nature Genetics 11(1): 64-70

In Preparation:

Yan H, Im WB, Nieves A, Reitmair A, Dinh D, Old D, Donde Y, Garst M, Wheeler L (in preparation) Cell type-dependent intracellular signaling pathways mediated by EP2 and EP4 in human primary cell cultures.

Im WB, Reitmair A, Nieves A, Yan H, Dinh D, Old D, Garst M, Wheeler L (in preparation) Pharmacology of the human EP3 subtype of the PGE2 receptor family explored with PGE2 and synthetic PGE2 analogs in HEK cells heterologously expressing three major isoforms, EP3-4, -5, and -7.

Reitmair A, Nehme A, Chandraratna RAS, Brown G (in preparation) Blockade of retinoic acid receptors improves recovery of leukopenic mice and protects these mice from Staphylococcus aureus infection.

Published Abstracts:

Lowsky R, Ichinohasama R, Reitmair AH, Decoteau JF (1997) Microsatellite instability does not predict for underlying MSH2 gene defects in tumors of hemato-lymphoid origin. Blood 90(10): 2176-2176

Lowsky R, Decoteau JF, Reitmair AH, Ichinohasama R, Dong WF, Xu Y, Mak TW, Kadin ME, Minden MD (1996) Mutations of hMSH2 in human lymphoblastic lymphomas. Blood 88(10): 1401-1401

Mayer KM, Reitmair A, Ansotegui IJ, Ballhausen WG (1992) Type II transcript-dependent expression of p56lck is regulated at the translational level by the 5' and 3' untranslated regions (UTR). Immunobiology 186: 163-163

Poster Presentations:

Kim Y, Ho SO, Kim T, Reitmair AH, Weiss S (2007) Development of a ultrasensitive, rapid, mix-and-read detection system for botulinum toxins. Pacific Southwest Regional Center of Excellence (PSWRCE) for Biodefense and Emerging Infectious Diseases Research, Third Annual Meeting, Oakland, CA.

Reitmair A, Shurland D-L, Tsang K-Y, Chandraratna RAS, Brown G (2005) A retinoid-related molecule that does not bind to classical retinoid receptors potently induces G2M arrest and apoptosis in bladder cancer cells. Keystone Symposia: “Cellular Senescence and Cell Death”, Keystone, Colorado, USA

Reitmair A, Cai JC, Redston M, Pind M, Hay K, Mitri A, Bjerknes M, Bapat B, Mak T, Gallinger S (1996) Msh2 deficiency increases tumorigenicity in the multiple intestinal neoplasia mouse. Annual AACR (American Association for Cancer Research) meeting, Washington D.C., USA

Andrew SE, Reitmair AH, Fox J, Hsiao L, Mak T, Jirik FR (1996) Analysis of spontaneous mutations in Msh2 "knock-out" mice using a transgenic mutation detection system. Gordon Research Conference on Mutagenesis, Plymouth, New Hampshire, USA

Reitmair AH, Schmits R, Ewel A, Bapat B, Redston M, Mitri A, Waterhouse P, Mittrücker H-W, Wakeham A, Liu B, Thomason A, Griesser H, Gallinger S, Ballhausen WG, Fishel R, Mak T (1995) Msh2 deficient mice are viable and susceptible to lymphoid tumours. AACR Conference: “Cancer: The Interface Between Basic and Applied Research”, Baltimore, Maryland, USA

Invited Lectures:

"Nesher Technologies Inc - Nanobiotech for Smarter Diagnostics and Cutting-edge Biomedical Research" (2016) 16th Annual New York Venture Summit, New York City, USA

"Next-generation Diagnostic and Analytical Systems for IVD and Research Markets" (2015) AdvaMed 2015, San Diego, USA

"Nesher Technologies Inc - Nanobiotech for Smarter Diagnostics and Cutting-edge Biomedical Research" (2014) Southern California Biomedical Council (SoCalBio), Los Angeles, California, USA

"Method for Analysis of Single Molecules in Bio-Medical Research" (2014) I-Corps at NIH, Washington, DC, USA

"Alternating Laser EXcitation (ALEX) Single Molecule Fluorescence Spectroscopy: Technology Review and its Use in Protein Folding Studies" (2014) ZING Conference on Protein Folding, Punta Cana, Dominican Republic

"Alternating Laser EXcitation (ALEX) Single-molecule Fluorescence Spectroscopy: Use in Basic Research and Medical Diagnostics" (2009) Medizinisch Genetisches Zentrum (MGZ), Munich, Germany

"New Promise for Revolution in Early Cancer Detection" (2005) Project T2 Conference, LARTA Institute, Los Angeles, California, USA

"Entwicklung und Analyse des ‘knock out’-Mausmodells für das Tumorsupressor- und DNA Reparatur-Gen Msh2" (1999) Boehringer Ingelheim, Biberach, Germany

"Lessons from Msh2 Knockout Mice: The Connection between DNA Mismatch Repair and Cancer" (1998) Allergan, Irvine, California, USA

"Knock-out Mausmodelle in der Krebsforschung" (1996) Merck, Darmstadt, Germany

"Hereditary Cancer Syndromes and Tumour Suppressor Genes" (1996) Centre des Etudes du Polymorphisme Humain (CEPH), Paris, France

"Die Rolle des Tumorsupressorgens Msh2 in der Tumorgenese" (1996) Institute of Human Genetics, Friedrich-Alexander-Universität, Erlangen, Germany

"Intestinal Tumors and Skin Neoplasms in Msh2 Deficient Mice" (1996) Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

"DNA Mismatch Repair and Cancer: What Msh2 Knockout Mice Tell Us" (1996) University of Utah, Salt Lake City, Utah, USA

"Msh2 Deficient Mice are Prone to Intestinal Tumours" (1996) Johns Hopkins University Hospital, Baltimore, Maryland, USA

"Msh2 Deficient Mice are Viable and Susceptible to Lymphoid Tumors" (1995) Amgen Inc., Thousand Oaks, California, USA

"Cancer Susceptibility in Msh2 Deficient Mice" (1995) Johns Hopkins University Hospital, Baltimore, Maryland, USA

"Targeted Inactivation of the Msh2 Gene in Mice" (1994) Amgen Inc., Thousand Oaks, California, USA

Memberships in Professional Associations:

American Association for Cancer Research (AACR)

American Society for Biochemistry and Molecular Biology (ASBMB)

Federation of American Societies for Experimental Biology (FASEB)

International Union of Biochemistry and Molecular Biology (IUBMB)

Federation of European Biochemical Societies (FEBS)

Gesellschaft für Biochemie und Molekularbiologie (GBM)

Society for Investigative Dermatology (SID)

References:

Professor Shimon Weiss UCLA (University of California Los Angeles)

Box 951569

607 Charles E. Young Drive East

Los Angeles, CA 90095-1569 - USA

Professor Tak Mak Ontario Cancer Institute/Princess Margaret Hospital

Rm 8-712

610 University Avenue

Toronto M5G 2M9 - CANADA

Professor Pierre Chambon IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire)

B.P.163

67404 Illkirch Cedex

C.U. de Strasbourg - FRANCE

Professor Hinrich Gronemeyer IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire)

B.P.163

67404 Illkirch Cedex

C.U. de Strasbourg - FRANCE

Professor Georg Fey Universität Erlangen - Institut für Genetik

Staudtstr. 5

91058 Erlangen - GERMANY

Professor Wolfgang Ballhausen Martin-Luther-Universität Halle-Wittenberg - Biozentrum

Weinbergweg 22

06120 Halle (Saale) - GERMANY

Contact this candidate